Gilberto Schwartsmann

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Andrea Wang‐Gillam, Chung‐Pin Li, G. Bodoky et al. · The Lancet · 2015 · 1.2K citations

Nanomedicine, Oncology, Pancreatic Cancer +8

Planning cancer control in Latin America and the Caribbean

Paul E. Goss, Brittany Lee, Tanja Badovinac-Črnjević et al. · The Lancet Oncology · 2013 · 496 citations · Full text

Preventive Medicine, Medicine, Global Health +7

Anti-Cancer Drug Discovery and Development in Brazil: Targeted Plant Collection as a Rational Strategy to Acquire Candidate Anti-Cancer Compounds

Dennis R.A. Mans, Adriana Brondani da Rocha, Gilberto Schwartsmann · The Oncologist · 2000 · 256 citations · Full text

Anti-cancer Drug Development, Chemoprevention Strategy, Anti-cancer Drug Discovery +18

A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients

Xavier Pivot, P. Koralewski, Jorge Hidalgo et al. · Annals of Oncology · 2008 · 179 citations · Full text

Breast Oncology, Medicine, Pharmacology +5

Anticancer drug discovery and development throughout the world.

Gilberto Schwartsmann, Mark J. Ratain, Gordon M. Cragg et al. · PubMed · 2002 · 150 citations

American Society, Cancer Registration, Therapeutic Area +16